Pioglitazone

ArtNr	HY-13956-50mg
Hersteller	MedChem Express
CAS-Nr.	111025-46-8
Menge	50 mg
Quantity options	10 mM/1 mL 10 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Cholesterol & Lipid Metabolism Regulation of Appetite Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Testicular & Prostate Cancer Neurodegeneration Markers
Typ	Inhibitors
Specific against	other
Purity	99.89
Citations	[1]Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve\|[2]Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84.\|[3]Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55.\|[4]Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. Acta Pharmacol Sin. 2021 Jan;42(1):160-170.\|Adv Sci (Weinh). 2024 Dec 25:e2407134.\|Adv Sci (Weinh). 2024 Oct 7:e2401931.\|Am J Physiol Heart Circ Physiol. 2021 Apr 9.\|Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F137-F151.\|Biochem Eng J. 2021, 108104.\|BMC Complement Med Ther. 2022 Jul 1;22(1):176.\|Br J Pharmacol. 2021 Jun;178(11):2305-2323.\|Cancer Res. 2022 Apr 15;82(8):1503-1517.\|Cell Metab. 2021 Mar 2;33(3):581-597.e9.\|Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.\|Food Chem Toxicol. 2021 Apr 6;112183.\|Gut Microbes. 2022, 14(1): 2139978.\|Heliyon. 2023 Apr 1.\|Immunology. 2023 Jan 28.\|Immunopharmacol Immunotoxicol. 2021 Aug 27;1-9.\|J Adv Res. 2024 Sep 29:S2090-1232(24)00427-2.\|J Ethnopharmacol. 2024 Nov 29:340:119128.\|J Steroid Biochem Mol Biol. 2023 Feb 1;229:106265.\|Med Sci Monit. 2019 Nov 13;25:8544-8553.\|Nutr Metab (Lond). 2019 Mar 5;16:17. \|Oxid Med Cell Longev. 2022.\|Res Sq. 2024 Jul 12.\|Research Square Preprint. 2021 Mar.\|SSRN. 2023 May 30.\|Tunku Abdul Rahman University. 2024 Mar 11.\|Inflammation. 2020 Apr;43(2):568-578.\|Int J Oncol. 2018 Aug;53(2):551-566.\|J Diabetes Res. 2019 Feb 3;2019:5245063.\|Mol Med Rep. 2024 Nov;30(5):209.\|Mol Med Rep. 2019 Jan;19(1):400-406.
Smiles	O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(CC)C=C3)C=C2)C1=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	U 72107
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Ferroptosis; PPAR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	356.44
Product Description	Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research[2][3][4].
Manufacturer - Research Area	Metabolic Disease; Cancer
Solubility	DMSO: 25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Isoform	PPARα; PPARβ/δ; PPARγ
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-13956-50mg-safety-datasheet.pdf